CD274 and gastric cancer: The link between the loss of ARID1A and MSI and TMB, together with PD-L1 expression, TILs and systemic inflammatory markers [46–48] increases its clinical and prognostic relevance as a marker for screening and therapeutic response to targeted therapy and immune checkpoint inhibitors in gastric cancer.